Brought to you by:
Long-awaited FDA update finds data do not support excess mortality risk for paclitaxel-coated devices
[vc_row][vc_column][vc_column_text] In a letter to healthcare providers dated July 11, 2023, the Food and Drug Administration (FDA) communicates that the risk of mortality associated with paclitaxel-coated devices to treat peripheral arterial disease (PAD) is no longer supported based on data…
VESAP5 expires July 14
The SVS’ fifth edition of the Vascular Education and Self- Assessment Program (VESAP5) expires at 9 a.m. CDT July 14 and with it, the possibility of claiming continuing medical education credits. Learners can earn credits and obtain certificates until then.…
Review urges development of protocols to reduce hypersensitivity reactions after cyanoacrylate varicose vein treatment
Despite being considered “generally safe,” cyanoacrylate can cause local reactions in up to 25% of patients, disproportionately affecting women, Asian race and thin patients with a body mass index of <22. This was the conclusion drawn by Eduardo Silva, MD,…
The top 10 most popular Vascular Specialist stories of June 2023
Last month, Vascular Specialist garnered readers’ attention with an array of commentary on the BEST-CLI and BASIL-2 trials; the medical editor’s interview with vascular surgery’s ‘living legend’ Frank J. Veith, MD; the news of the death of Past SVS President…
Surmodics receives FDA approval for the SurVeil drug-coated balloon
Surmodics has announced the receipt of Food and Drug Administration (FDA) approval for the SurVeil drug-coated balloon (DCB). A company press release notes that the SurVeil DCB may now be marketed and sold in the U.S. to physicians for percutaneous…
FDA approves study of ZFEN+ for treatment of aortic aneurysms
The Food and Drug Administration (FDA) has granted approval for Cook Medical to initiate an investigational device exemption (IDE) study on the Zenith fenestrated+ endovascular graft (ZFEN+). The clinical study will assess the safety and effectiveness of the ZFEN+ in…
SVS mourns death of Past President Kenneth Wayne Johnston
The Society for Vascular Surgery (SVS) mourns the death of Kenneth Wayne Johnston, an SVS member, former president and recipient in 2009 of the SVS’ highest honor, the Lifetime Achievement Award. Barry Rubin, MD, chair and program medical director for…
Risk of cancer-related VTE recurrence ‘significantly lower’ using NOACs compared with low molecular weight heparin
Delivering results and recommendations from a systematic review and meta-analysis of novel oral anticoagulants (NOACs) versus low molecular weight heparin (LMWH) in the prevention of venous thromboembolism (VTE) recurrence in cancer patients, Patricia Noreen Bueno, MD, from St Luke’s Medical…
Vascular Verification Program registers first four hospitals in US—including UCSF
UC San Francisco Medical Center (UCSF) is among the first four hospitals in the U.S. to be verified as part of the American College of Surgeons’ (ACS) Vascular Verification Program (Vascular-VP), a quality program recently launched in partnership with the Society for…
Assessing the needs of young vascular patients
In the past 18 months, a joint taskforce studying the needs of pediatric vascular patients has made great strides, conducting a needs assessment, identifying top priorities and planning resources for surgeons of these young patients. The next step: a meeting…